Despite the limited number of patients receiving MEK inhibitor-based therapy, those with metastatic KRAS+ NSCLC tended to have better responses than did those with metastatic KRAS- NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.